Please click on the ID to see detailed information about each entry.
The total number entries retrieved from this search are| ID | Sequence | Name | Nature of peptide or cargo | Assay | Tissue permeability | Tissue Sample | PUBMED ID |
|---|---|---|---|---|---|---|---|
| 1013 | GKKKRRRR | R8 (arginine-terminated peptide dendrimers) | Peptide dendrimers are wedge-like molecules comprising an amino acid branching core that is most typically decorated with various basic amino acids (e.g. Lys, His, Arg) on their head groups | Franz diffusion cell | Flux (mg/cm2/h) ± 4.83 , Q48(mg) 2706.53 ± 123.60, Drug content in skin (mg/cm2) 204 ± 8.41 | Human epidermal skin | 24134794 |
| 1014 | GKKKRRRR | R8 (arginine-terminated peptide dendrimers) | Peptide dendrimers are wedge-like molecules comprising an amino acid branching core that is most typically decorated with various basic amino acids (e.g. Lys, His, Arg) on their head groups | Franz diffusion cell | Flux (mg/cm2/h) 57.66 ± 4.83 , Q48(mg) 2706.53 ± 123.60, Drug content in skin (mg/cm2) 204 ± 8.41 | Human epidermal skin | 24134794 |
| 1015 | GKKKRRRR | R8 (arginine-terminated peptide dendrimers) | Peptide dendrimers are wedge-like molecules comprising an amino acid branching core that is most typically decorated with various basic amino acids (e.g. Lys, His, Arg) on their head groups | Franz diffusion cell | Flux (mg/cm2/h) 78.07 ± 7.52, Q48 (mg) 3666.44 ± 162.70 Drug content in skin (mg/cm2) 378± 15.11 | Human epidermal skin | 24134794 |
| 1076 | RRRRRRRR | Polyarginine | Cell penetrating peptide | Franz cell system | The SC, epidermal and dermal retention of SP for SP-NLC-R11 was 10.92, 7.02 and 0.82 mg/g of skin, respectively and the SC, epidermal and dermal retention of KP for KP-NLC-R11 was 0.75, 0.44 and 0.17 mg/g of skin, respectively | Skin from the dorsal surface of hairless rat | 22617521 |
| 1091 | RKKRRQRRR | Tat | Tat-SOD is anti-inflammatory | Histochemical analysis | Significant permeability of the Tat-SOD peptide can be seen in histochemical images | Ear of mice | 22189681 |
| 1092 | RKKRRQRRR | Tat | For promoting the skin penetration of molecules | Franz diffusion cells, HPLC | Permeation parameters observed were 15.74 ± 1.31% | Dorsal skin of mice | 22072881 |
| 1093 | RKKRRQRRR | Tat | For promoting the skin penetration of molecules | Franz diffusion cells, HPLC | Permeation parameters observed were5.74 ± 1.32% | Dorsal skin of mice | 22072881 |
| 1094 | RKKRRQRRR | Tat | For promoting the skin penetration of molecules | In vivo therapeutic efficacy assay | Show significantly improvement in wound and dry skin | Postaxial back skin of the mice | 22072881 |
| 1095 | RKKRRQRRR | Tat | For promoting the skin penetration of molecules | In vivo therapeutic efficacy assay | Show significantly improvement in wound and dry skin but lesser than EL/T | Postaxial back skin of the mice | 22072881 |
| 1103 | CGLHPAFQC | TDA1 | Anti-obesity treatment, Adipose tissue-targeting property and transdermal capacity | Franz cell system | Appearing frequency in the analyzed peptide pool (%) 28/280 (10) | Abdominal skin surface of male wistar rats | 21999821 |
| 1117 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 64.9±8.8% degraded | Interior skin surface of dermatomed skin (DS) of porcine | 19486932 |
| 1118 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 15±4.1% degraded | Interior skin surface of heat separated epidermis (HSE) of porcine | 19486932 |
| 1119 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 100% degraded | Interior skin surface of full thickness skin (FTS) of porcine | 19486932 |
| 1120 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 87.8±4.4% degraded | Interior skin surface of dermatomed skin (DS) of porcine | 19486932 |
| 1121 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 51.3±6% degraded | Interior skin surface of heat separated epidermis (HSE) of porcine | 19486932 |
| 1143 | r–nle–nle–nle–r–nle–nle–nle–g–y | RDP58 | Immunomodulator | Histological assay using bright field microscopy | It can be clearly seen from the histological images that topical application of RDP58results in significant decrease in tthe hickness of the ear skin as compared to control (TPA applied ear skin) | Ear of mice | 16117788 |
| 1145 | SIINFEKL | OVA257–264 | It is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA), presented by the class I major histocompatibility complex (MHC) molecule, H-2Kb. | ELISPOT assay | ~ 210 spots/1*106 total cells(4 folds more than the permeability of the peptide with vehicle alone) | Epidermal layer of naive C57BL mice | 16113599 |
| 1146 | SIINFEKL | OVA257–264 | It is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA), presented by the class I major histocompatibility complex (MHC) molecule, H-2Kb. | ELISPOT assay | ~ 65 spots/1*106 total cells | Epidermal layer of naive C57BL mice | 16113599 |
| 1147 | SIINFEKL | OVA257–264 | It is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA), presented by the class I major histocompatibility complex (MHC) molecule, H-2Kb. | ELISPOT assay | ~ 51 spots/1*106 total cells | Epidermal layer of naive C57BL mice | 16113599 |
| 1148 | SIINFEKL | OVA257–264 | It is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA), presented by the class I major histocompatibility complex (MHC) molecule, H-2Kb. | ELISPOT assay | ~ 100 spots/1*106 total cells | Epidermal layer of naive C57BL mice | 16113599 |
| 1149 | SIINFEKL | OVA257–264 | It is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA), presented by the class I major histocompatibility complex (MHC) molecule, H-2Kb. | ELISPOT assay | ~ 200 spots/1*106 total cells | Epidermal layer of naive C57BL mice | 16113599 |
| 1150 | SIINFEKL | OVA257–264 | It is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA), presented by the class I major histocompatibility complex (MHC) molecule, H-2Kb. | ELISPOT assay | ~ 215 spots/1*106 total cells | Epidermal layer of naive C57BL mice | 16113599 |
| 1151 | SIINFEKL | OVA257–264 | It is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA), presented by the class I major histocompatibility complex (MHC) molecule, H-2Kb. | ELISPOT assay | ~ 65 spots/1*106 total cells | Epidermal layer of naive C57BL mice | 16113599 |
| 1194 | Mpr-YFQNCPrG | Desmopressin | It is a peptide hormone that is used chiefly for treatment of enuresis | Radioimmunoassay | 10 ng/ml serum conc. of desmopressin after ~100 min of coated microneedle array application | Lateral skin areas of the thorax of hairless guinea pigs | 15212882 |
| 1195 | Mpr-YFQNCPrG | Desmopressin | It is a peptide hormone that is used chiefly for treatment of enuresis | Radioimmunoassay | 1 ng/ml serum conc. of desmopressin after ~250 min of coated microneedle array application | Lateral skin areas of the thorax of hairless guinea pigs | 15212882 |
| 1196 | Mpr-YFQNCPrG | Desmopressin | It is a peptide hormone that is used chiefly for treatment of enuresis | Radioimmunoassay | 0.8 ng/ml serum conc. of desmopressin after ~350 min of coated microneedle array application | Lateral skin areas of the thorax of hairless guinea pigs | 15212882 |
| 1197 | SIINFEKL | OVA8 | OVA8 peptides can be used to detect a strong CD8+ cytolytic T cell response | Histochemical staining | Distributed uniformly on the skin surface without obvious penetration into deeper layers of the epidermis or the dermis. | Tape-stripped ears of mice | 15121311 |
| 1199 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 2.37 ± 0.94 µg h−1 cm−2 at 100% DC | Human cadaver skin | 14757511 |
| 1200 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 9.87 ± 4.91 µg h−1 cm−2 at 75% pulsed DC | Human cadaver skin | 14757511 |
| 1201 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 5.57 ± 2.27 µg h−1 cm−2 at 50% pulsed DC | Human cadaver skin | 14757511 |
| 1202 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 1.21 ± 0.76 µg h−1 cm−2 at 75%+/25%− AC | Human cadaver skin | 14757511 |
| 1203 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 0.006 ± 0.004 µg h−1 cm−2 at 50%+/50%− AC | Human cadaver skin | 14757511 |
| 1204 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 1.99 ± 2.04 µg h−1 cm−2 at 100% DC | Human cadaver skin | 14757511 |
| 1205 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 6.47 ± 0.87 µg h−1 cm−2 at 75% DC | Human cadaver skin | 14757511 |
| 1206 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 0.96 ± 0.79 µg h−1 cm−2 at 50% pulsed DC | Human cadaver skin | 14757511 |
| 1207 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 3.33 ± 1.04 µg h−1 cm−2 at 75%+/25%- AC | Human cadaver skin | 14757511 |
| 1208 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 0.15 ± 0.09 µg h−1 cm−2 at 50%+/50%- AC | Human cadaver skin | 14757511 |
| 1209 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 12.39 ± 5.32 µg h−1 cm−2 at 75% pulsed DC (500 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1210 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 5.97 ± 3.20 µg h−1 cm−2 at 50% pulsed DC (500 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1211 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux=9.07 ± 4.28 µg h−1 cm−2 at 25% pulsed DC (500 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1212 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 8.70±3.56 µg h−1 cm−2 at 75% pulsed DC (5 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1213 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 7.31±1.94 µg h−1 cm−2 at 50% pulsed DC (5 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1214 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 9.35±1.98 µg h−1 cm−2 at 25% pulsed DC (5 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1259 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Algesic response: ~15(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. Maximal painful response was attained 1-2 minutes after drug administration and faded after 5 minutes. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1260 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Algesic response: ~22(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. Maximal painful response was attained 1-2 minutes after drug administration and faded after 5 minutes. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1261 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin vehicle pretreatment: ~15.3(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1262 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin pretreatment((50 nmol in 50 µl, everyday for 5-7 days): ~10.7(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1263 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin vehicle pretreatment: ~22(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1264 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin pretreatment((50 nmol in 50 µl, everyday for 5-7 days): ~20(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
| 1295 | HDMNKVLDL | Nonapeptide P2 or AF-2 | Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally. | MPO and NAG assays | MPO levels(mU/ear)=Untreated(0.03)/Treated(1.72 ± 0.20), PGE2 levels(ng/ear)=Untreated(0)/Treated(83.2 ± 2.8), LTB4 levels(ng/ear)=Untreated(0)/Treated(15.2 ± 1.2) | Ear(auditory pinna) of male Swiss Webster mice | 7646536 |